Amarin Corporation PLC
AMRN15.140USD
-0.020-0.13%
Market hours （ET）Quotes delayed by 15 min
314.46MMarket Cap
LossP/E TTM
More Details of Amarin Corporation PLC Company
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Company Info
Ticker SymbolAMRN
Company nameAmarin Corporation PLC
IPO dateApr 01, 1993
CEOMr. Aaron D. Berg
Number of employees275
Security typeDepository Receipt
Fiscal year-endApr 01
AddressWeWork One Central Plaza Dame Street
CityDUBLIN
Stock exchangeNASDAQ Capital Market Consolidated
CountryIreland
Postal codeD02 K7K5
Phone35316699020
Websitehttps://amarincorp.com/
Ticker SymbolAMRN
IPO dateApr 01, 1993
CEOMr. Aaron D. Berg
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Keith L. Horn
Mr. Keith L. Horn
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sarissa Capital Management, L.P.
6.01%
Kynam Capital Management LP
3.00%
Acadian Asset Management LLC
0.92%
Eversept Partners, LP
0.82%
Two Sigma Investments, LP
0.79%
Other
88.47%
Shareholders
Shareholders
Proportion
Sarissa Capital Management, L.P.
6.01%
Kynam Capital Management LP
3.00%
Acadian Asset Management LLC
0.92%
Eversept Partners, LP
0.82%
Two Sigma Investments, LP
0.79%
Other
88.47%
Shareholder Types
Shareholders
Proportion
Hedge Fund
11.52%
Investment Advisor
3.36%
Investment Advisor/Hedge Fund
1.67%
Research Firm
0.96%
Individual Investor
0.95%
Pension Fund
0.14%
Family Office
0.10%
Bank and Trust
0.01%
Venture Capital
0.01%
Other
81.27%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
335
3.85M
18.62%
-1.48M
2025Q1
349
5.67M
20.22%
+144.25K
2024Q4
362
81.89M
19.91%
-21.31M
2024Q3
365
76.69M
18.66%
-50.88M
2024Q2
389
87.45M
21.29%
-59.57M
2024Q1
405
98.68M
24.03%
-57.40M
2023Q4
423
103.82M
25.42%
-56.37M
2023Q3
447
95.61M
23.44%
-78.96M
2023Q2
464
107.90M
26.46%
-89.05M
2023Q1
492
118.85M
29.19%
-104.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sarissa Capital Management, L.P.
1.24M
6%
--
--
Mar 31, 2025
Kynam Capital Management LP
620.73K
3%
--
--
Mar 31, 2025
Acadian Asset Management LLC
189.58K
0.92%
+100.29K
+112.31%
Mar 31, 2025
Eversept Partners, LP
169.96K
0.82%
+94.13K
+124.13%
Mar 31, 2025
Two Sigma Investments, LP
162.85K
0.79%
-33.32K
-16.99%
Mar 31, 2025
WaterFront Wealth, Inc.
125.73K
0.61%
+1.64K
+1.32%
Mar 31, 2025
SCP Investment, LP
125.00K
0.6%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
116.05K
0.56%
-87.42K
-42.96%
Mar 31, 2025
Longitude (Cayman) Ltd
81.00K
0.39%
-37.50K
-31.65%
Dec 31, 2024
Berg (Aaron D.)
80.71K
0.39%
+36.64K
+83.12%
Jun 26, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
SPDR S&P International Small Cap ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0%
Global X Aging Population ETF
0%
ActivePassive International Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
AltShares Event-Driven ETF
0%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
SPDR S&P International Small Cap ETF
Proportion0.01%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
Global X Aging Population ETF
Proportion0%
ActivePassive International Equity ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
AltShares Event-Driven ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 12, 2025
Merger
20<1
Date
Type
Ratio
Mar 12, 2025
Merger
20<1
